Abstract 58P
Background
There is an increasing incidence of RC in the young. Clinicopathologic features are not clearly established especially in the local Filipino population. Moreover, treatment challenges occur in this population. This study aims to describe the clinicopathologic profile and outcomes in patients diagnosed with RC in the young at the Southern Philippines Medical Center, Adult Cancer Institute.
Methods
All RC patients were reviewed from January 2018 to December 2021. A total of 548 RC patients were reviewed retrospectively.
Results
A total of 99 patients were identified (18%) as RC in the young. Majority were males (68%) and have a family history of cancer (72%). Mean tumor distance was 4.82+6.0 cm from the anal verge. All patients had adenocarcinoma histology with 9% having mucinous component and 1% with signet ring features. For tumor differentiation, 56% had moderately and 23% had poorly differentiated tumors. Most patients were diagnosed with locally advanced disease (55% St IIIB, 12% St IIIC) and 24% with distant metastasis. Mean CEA levels were elevated (preoperative 59.44ng/ml and post-operative 49.42ng/ml). Among non-metastatic disease, most stage II and stage III RC patients received neoadjuvant long course chemoradiation (LCCRT) then Surgery then adjuvant chemotherapy (AC) (52%). Most common AC used was Capecitabine-Oxaliplatin. At the time of analysis, 57.6% had no evidence of disease while 38.4% progressed or metastasized to distant organs. In the overall population of RC in the young, median overall survival was 21.3 months (mos). Survival rate at 12 mos was 60% and at 24 mos was 40%.
Conclusions
RC in the young Filipino patient presented more with lower lying rectal tumors, moderately to poorly differentiated histology, and more advanced disease at diagnosis. Survival appeared to be worse compared to historical data. Improved understanding of this specific subgroup is necessary for better treatment options and outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
79P - Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
Presenter: Arndt Vogel
Session: Poster viewing 02
82P - A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX
Presenter: Muh-Hwan Su
Session: Poster viewing 02
83P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster viewing 02
84P - Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
Presenter: Margherita Rimini
Session: Poster viewing 02
86P - Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster viewing 02
87P - Socio-demographic disparities in esophageal cancer: A SEER analysis
Presenter: Beas Siromoni
Session: Poster viewing 02
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02